We report significant findings on the beneficial impact of PD-L1 expression in tumor-infiltrating macrophages and the detrimental effects of CD86-positive macrophages on overall survival among patients treated with dendritic cell-based immunotherapy. This evidence concerns the gene CD86 and neoplasm.